A Phase 2 interventional study of Azacitidine in Myelodysplastic Syndrome (MDS), sponsored by Celgene. Completed at 11 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-19.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 130 studies testing azacitidine in Myelodysplastic Syndromes — 13 open to participants now, 25 under way, 3 of them phase 3. Azacitidine · Myelodysplastic Syndromes.
Among the 130 studies testing azacitidine in Myelodysplastic Syndromes, this one is the 28th largest by enrollment of the 126 interventional ones that give a count, is one of 10 that started in 2012, is one of 63 in phase 2, and was the 58th registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.
Browse Myelodysplastic Syndromes studies →13 of the 130 studies testing azacitidine in Myelodysplastic Syndromes are open now, in 12 countries. Recruiting first, the newest first:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70
City of Hope Medical Center · Sites in United States
Ages 18–75
Medical College of Wisconsin · Sites in United States
Ages 18+
Institut de Recherches Internationales Servier · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Beijing 302 Hospital · Sites in China
Ages 18–70
By country, each count listing its studies:
Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
130 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 50 · Phase 2 86 · Phase 3 12 · Phase 4 3
First in 2000; this study’s year is marked. 10 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is above the median of 40 across 1,611 interventional studies indexed under Myelodysplastic Syndromes.
Median enrollment 38 across the 126 interventional studies. Of the 88 that completed or were terminated, 42 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 130 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb: 4 open now, 9 under way, 5 of them phase 3. Of 63 finished, 20 (32%) have results posted.
Among the 75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb, this one is the 20th largest by enrollment of the 46 interventional ones that give a count, is one of 6 that started in 2012, is one of 14 in phase 2, and was the 29th registered.
Bristol-Myers Squibb’s Myelodysplastic Syndromes studies by the year they started, since 2001.
9 of the studies testing azacitidine in Myelodysplastic Syndromes that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06465953Phase 3Institut de Recherches Internationales ServierIvosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation | 2027-11-01 |
| NCT05788679Karolinska University HospitalA Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS | 2026-12 |
| NCT00392353National Cancer Institute (NCI)Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | 2026-12-31 |
| NCT06502145Medical College of WisconsinIadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome | 2026-12-31 |
| NCT03862157M.D. Anderson Cancer CenterAzacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | 2027-01-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 130 studies testing azacitidine in Myelodysplastic Syndromes, from their registry updates:
Among Bristol-Myers Squibb’s 75 in Myelodysplastic Syndromes:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to determine whether azacitidine is safe and effective in the treatment of Chinese patients with higher risk Myelodysplastic Syndromes (MDS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must satisfy the following criteria to be enrolled in the study:
Must have a documented diagnosis of anemia with excess blasts (RAEB) or refractory anemia with excess blasts in transformation (RAEB-T) according to French-American-British (FAB) classification for Myelodysplastic Syndrome (MDS) and with an International Prognostic Scoring System (IPSS) score of intermediate-2 or high risk or a diagnosis of myelodysplastic chronic myelomonocytic leukemia (CMML) per modified FAB criteria meeting the following:
Exclusion Criteria:
The presence of any of the following will exclude a subject from enrollment:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Azacitidine 75 mg/m\^2/day subcutaneously (SC) for 7 days every 28 days until disease progression (DP), adverse events (AE), withdrawal of consent from further treatment, withdrawal of consent, death, lost to follow-up, or protocol violation.
Drug: Azacitidine
Subcutaneous administration of azacitidine 75 mg/m\^2/day for 7 days every 28 days optimally for at least 6 cycles until disease progression, unacceptable toxicity, or treatment discontinuation for any other reason
Also known as: Vidaza
Percentage of Participants With a Hematologic Response Based on the International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS) and Programmatically Assessed by the Sponsor Using Clinically Relevant Data.
Hematologic Response is defined by those participants who experienced a Complete Response, Partial Response and Stable Disease (SD) based on IWG 2000 response criteria for MDS. CR = repeat bone marrow (BM) shows \<5% myeloblasts, and peripheral blood values lasting ≥ 2 months of hemoglobin (hgb) (\>110 g/L), neutrophils (≥1.5x10\^9/L), platelets (≥100x10\^9/L), blasts (0%) and no dysplasia • PR = same as CR for peripheral blood: BM shows blasts decrease by ≥ 50% or a less advanced FAB classification from pretreatment • Stable disease (SD): failure to achieve a PR, no evidence of progression for at least 2 months. • Failure: death during treatment or disease progression • Relapse After CR or PR: return to pretreatment BM blast percent or decrement of ≥ 50% from remission/response levels in granulocytes or platelets; or reduction in hgb by ≥20 g/L or transfusion dependence • Disease Progression: change in blast levels • Disease Transformation to Acute Myelogenous Leukemia.
Time frame: Response initially assessed at end of cycle 6, then every 4 cycles; Up to 29 January 2015; 894 days
Percentage of Participants With a Hematologic Response Using IWG Criteria for MDS and Assessed by the Investigator
Hematologic Response is defined by those participants who experienced a Complete Response, Partial Response and Stable Disease (SD) based on IWG 2000 response criteria for MDS. CR = repeat bone marrow (BM) shows \<5% myeloblasts, and peripheral blood values lasting ≥ 2 months of hemoglobin (hgb) (\>110 g/L), neutrophils (≥1.5x10\^9/L), platelets (≥100x10\^9/L), blasts (0%) and no dysplasia • PR = same as CR for peripheral blood: BM shows blasts decrease by ≥ 50% or a less advanced FAB classification from pretreatment • Stable disease (SD): failure to achieve a PR, no evidence of progression for at least 2 months. • Failure: death during treatment or disease progression • Relapse After CR or PR: return to pretreatment BM blast percent or decrement of ≥ 50% from remission/response levels in granulocytes or platelets; or reduction in hgb by ≥20 g/L or transfusion dependence • Disease Progression: change in blast levels • Disease Transformation to Acute Myelogenous Leukemia.
Time frame: Response initially assessed at end of cycle 6, then every 4 cycles; Up to 29 January 2015; 894 days
Percentage of Participants Achieving a Hematologic Improvement (HI) Based on 2000 IWG Response Criteria for MDS and Programmatically Assessed by the Sponsor Using Clinically Relevant Data.
Hematologic improvements (HI) have 4 categories: 1. Erythroid response (HI-E): Major \>20g/L increase or transfusion independent. Minor: 10-20g/L increase or ≥50% decrease in transfusion requirements. 2. Platelet response (HI-P): Major absolute increase of ≥30x10\^9/L or platelet transfusion independence. Minor: ≥50% increase. 3. Neutrophil response (HI-N): Major 100% increase or an absolute increase of \>0.5x10\^9/L. Minor: ≥100% increase and absolute increase of \<0.5x10\^9/L 4. Progression or relapse after HI Hematological improvement (HI) was defined as any type (major or minor) of improvement of HI-E, HI-P, or HI-N. Criteria: Pretreatment=hemoglobin \<100g/L or RBC transfusion-dependent, platelet count \<100x10\^9/L or platelet transfusion dependent, absolute neutrophil count \<1.5x10\^9/L. Sponsor's determination was derived using clinically relevant data. Denominator for progression/relapse after HI included participants who had achieved HI.
Time frame: Up to 29 January 2015; 894 days
The Number of Units of Platelet Transfusions by Cycle
The number of units of platelet transfusions received 56 days prior to treatment, considered the baseline period, (baseline period defined as the screening period before the date of the first dose of azacitidine; any laboratory and blood transfusion data reported on the day of the first dose of azacitidine was considered to be baseline data) and during study was standardized per 28 days and summarized by cycle for platelets. The formula for standardizing per 28 days was: \[(# of transfusions in the measurement period / length of the measurement period (days)) x 28\], where the measurement period was either baseline or the relevant cycle length.
Time frame: Up to cycle 27; The on-treatment period was considered the period from the date of first dose to the last treatment study visit; Up to 29 January 2015; 894 days
The Number of Platelet Transfusions by Cycle
The number of platelet transfusions received 56 days prior to treatment, considered the baseline period (baseline period defined as the screening period before the date of the first dose of azacitidine; any laboratory and blood transfusion data reported on the day of the first dose of azacitidine was considered to be baseline data) and during study was standardized per 28 days and summarized by cycle for platelets. The formula for standardizing per 28 days was: \[(# of transfusions in the measurement period / length of the measurement period (days)) x 28\], where the measurement period was either baseline or the relevant cycle length.
Time frame: Up to cycle 27; The on-treatment period was considered the period from the date of first dose to the last treatment study visit; Up to 29 January 2015; 894 days
The Number of Units of Red Blood Cell (RBC) Transfusions by Cycle
The number of units of RBC received 56 days prior to treatment, considered the baseline period (baseline period defined as the screening period before the date of the first dose of azacitidine; any laboratory and blood transfusion data reported on the day of the first dose of azacitidine was considered to be baseline data) and during study was standardized per 28 days and summarized by cycle for RBC. The formula for standardizing per 28 days was: \[(# of transfusions in the measurement period / length of the measurement period (days)) x 28\], where the measurement period was either baseline or the relevant cycle length.
Time frame: Up to cycle 27; The on-treatment period was considered the period from the date of first dose to the last treatment study visit; Up to 29 January 2015; 894 days
The Number of RBC Transfusions by Cycle
The number of RBC transfusions received 56 days prior to treatment, considered the baseline period (baseline period defined as the screening period before the date of the first dose of azacitidine; any laboratory and blood transfusion data reported on the day of the first dose of azacitidine was considered to be baseline data) and during study was standardized per 28 days and summarized by cycle for platelets. The formula for standardizing per 28 days was: \[(# of transfusions in the measurement period / length of the measurement period (days)) x 28\], where the measurement period was either baseline or the relevant cycle length.
Time frame: Up to cycle 27; The on-treatment period was considered the period from the date of first dose to the last treatment study visit; Up to 29 January 2015; 894 days
The Number of Infections (Post-baseline Average) Requiring Intravenous (IV) Antibiotics, Anti-fungals, or Antivirals by Cycle
The on-treatment adverse event of infection requiring IV antibiotics, antifungals, or antivirals per 28 days/cycle. The overall post-baseline average is the average of number of infections requiring IV antibiotics or IV antiviral per 28 days/cycle.
Time frame: Up to cycle 27; The on-treatment period was considered the period from the date of first dose to the last treatment study visit; Up to 29 January 2015; 894 days
Kaplan Meier Estimates for Overall Survival (OS)
Overall survival is defined as time to death from any cause, is calculated using date of first dose and date of death, or date of last follow-up for censored participants. Those, who die regardless of the cause of death, will be considered to have an event.
Time frame: Until the end of the survival follow-up period; Up to data cut-off of 29 January 2015; 894 days
Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Parent Phase
A treatment-emergent adverse events (TEAE) was defined as AEs with an onset date on or after the date of first dose and within 28 days after the date of the last dose. Any AE that occurred beyond this timeframe and was assessed by the investigator as possibly related to study drug was considered treatment-emergent. The intensity and severity of AEs was assessed by the investigator according to the Common Terminology Criteria for Adverse Event (CTCAE) Version 4.0. For any AEs not listed in the CTCAE grading system, the intensities of these events was assessed by the Investigator using the 5-point scale: Grade 1 = Mild, Grade 2 = Moderate; Grade 3 = Severe, Grade 4 = Life threatening, Grade 5 = Death. An SAE is any AE occurring that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and constitutes an important medical event.
Time frame: Up to 29 January 2015; from the first dose of study drug to 28 days after the date of the last dose of study drug (maximum time on study was 244 days)
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of Azacitidine
Area under the plasma concentration-time curve from time zero to infinity (AUC∞) following multiple doses of Azacitidine on Day 7; if possible, the area under the concentration-time curve from time zero to infinity, calculated by the linear trapezoidal rule and extrapolated to infinity was calculated according to the following equation: AUC∞ = AUCt + (Ct/ λz ), where Ct is the last quantifiable concentration. No AUC extrapolation will be performed with unreliable λz. If % AUC extrapolated is ≥ 25%, AUC∞ will not be reported
Time frame: PK blood samples collected at 0.25, 0.5, 1,2,3,4, 6 and 8 hours after azacitidine administration on Day 7
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUCt) of Azacitidine
Area under the plasma concentration-time curve from time zero to the last quantifiable time point, calculated by the linear trapezoidal rule when concentrations are increasing and the logarithmic trapezoidal method when concentrations are decreasing.
Time frame: PK blood samples collected at 0.25, 0.5, 1,2,3,4, 6 and 8 hours after azacitidine administration on Day 7
Maximum Observed Plasma Concentration (Cmax) of Azacitidine
The observed maximum plasma concentration obtained directly from the observed concentration versus time data.
Time frame: PK blood samples collected at 0.25, 0.5, 1,2,3,4, 6 and 8 hours after azacitidine administration on Day 7
Time to Maximum Plasma Concentration (Tmax) of Azacitidine
Time to maximum observed plasma concentration obtained directly from the observed concentration versus time data.
Time frame: PK blood samples collected at 0.25, 0.5, 1,2,3,4, 6 and 8 hours after azacitidine administration on Day 7
Terminal Phase of Half-life (T1/2) of Azacitidine
The apparent terminal half-life was calculated according to the following equation t½ = 0.693/λz.
Time frame: PK blood samples collected at 0.25, 0.5, 1,2,3,4, 6 and 8 hours after azacitidine administration on Day 7
Apparent Total Plasma Clearance (CL/F) of Azacitidine
Apparent total plasma clearance (CL/F) of Azacitidine was calculated as Dose/AUC∞
Time frame: PK blood samples collected at 0.25, 0.5, 1,2,3,4, 6 and 8 hours after azacitidine administration on Day 7
Apparent Volume of Distribution (Vd/F) of Azacitidine
Apparent volume of distribution, was calculated according to the equation: Vd/F = (CL/F)/λz
Time frame: PK blood samples collected at 0.25, 0.5, 1,2,3,4, 6 and 8 hours after azacitidine administration on Day 7
Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Extension Phase
A treatment-emergent adverse events (TEAE) was defined as AEs with an onset date on or after the date of first dose and within 28 days after the date of the last dose. Any AE that occurred beyond this timeframe and was assessed by the investigator as possibly related to study drug was considered treatment-emergent. The intensity and severity of AEs was assessed by the investigator according to the Common Terminology Criteria for Adverse Event (CTCAE) Version 4.0. For any AEs not listed in the CTCAE grading system, the intensities of these events was assessed by the Investigator using the 5-point scale: Grade 1 = Mild, Grade 2 = Moderate; Grade 3 = Severe, Grade 4 = Life threatening, Grade 5 = Death. An SAE is any AE occurring that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and constitutes an important medical event.
Time frame: Up to final data cut off date of 25 April 2018; from the first dose of study drug extesnion of 29 December 2014 to 28 days after the date of the last dose of study drug; median duration of any dose of study drug was 169 days
| Milestone | Azacitidine |
|---|---|
| Started | 72 |
| Intent to treat (itt) population | 72 |
| Pharmacokinetic (pk) population | 12 |
| Completed | 15 |
| Not completed | 57 |
| Withdrew: Adverse event | 5 |
| Withdrew: Disease progression | 7 |
| Withdrew: Withdrawal by subject | 20 |
| Withdrew: Death | 13 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Lack of therapeutic effect | 9 |
| Withdrew: Other | 2 |
| Milestone | Azacitidine |
|---|---|
| Started | 15 |
| Completed | 0 |
| Not completed | 15 |
| Withdrew: Study closure | 1 |
| Withdrew: Stopped to receive stem cell transplant | 1 |
| Withdrew: Lack of therapeutic effect | 4 |
| Withdrew: Disease progression | 1 |
| Withdrew: Withdrawal by subject | 8 |
Hematologic Response is defined by those participants who experienced a Complete Response, Partial Response and Stable Disease (SD) based on IWG 2000 response criteria for MDS. CR = repeat bone marrow (BM) shows \<5% myeloblasts, and peripheral blood values lasting ≥ 2 months of hemoglobin (hgb) (\>110 g/L), neutrophils (≥1.5x10\^9/L), platelets (≥100x10\^9/L), blasts (0%) and no dysplasia • PR = same as CR for peripheral blood: BM shows blasts decrease by ≥ 50% or a less advanced FAB classification from pretreatment • Stable disease (SD): failure to achieve a PR, no evidence of progression for at least 2 months. • Failure: death during treatment or disease progression • Relapse After CR or PR: return to pretreatment BM blast percent or decrement of ≥ 50% from remission/response levels in granulocytes or platelets; or reduction in hgb by ≥20 g/L or transfusion dependence • Disease Progression: change in blast levels • Disease Transformation to Acute Myelogenous Leukemia.
| percentage of participants | Azacitidine |
|---|---|
| Overall CR+PR | 1.4 (0.0 to 7.5) |
| Overall CR+PR+SD | 95.8 (88.3 to 99.1) |
| Complete Remission (CR) | 1.4 (0.0 to 7.5) |
| Partial Remission (PR) | 0 (0.0 to 5.0) |
Hematologic Response is defined by those participants who experienced a Complete Response, Partial Response and Stable Disease (SD) based on IWG 2000 response criteria for MDS. CR = repeat bone marrow (BM) shows \<5% myeloblasts, and peripheral blood values lasting ≥ 2 months of hemoglobin (hgb) (\>110 g/L), neutrophils (≥1.5x10\^9/L), platelets (≥100x10\^9/L), blasts (0%) and no dysplasia • PR = same as CR for peripheral blood: BM shows blasts decrease by ≥ 50% or a less advanced FAB classification from pretreatment • Stable disease (SD): failure to achieve a PR, no evidence of progression for at least 2 months. • Failure: death during treatment or disease progression • Relapse After CR or PR: return to pretreatment BM blast percent or decrement of ≥ 50% from remission/response levels in granulocytes or platelets; or reduction in hgb by ≥20 g/L or transfusion dependence • Disease Progression: change in blast levels • Disease Transformation to Acute Myelogenous Leukemia.
| percentage of participants | Azacitidine |
|---|---|
| Overall CR+PR | 12.5 (5.9 to 22.4) |
| Overall CR+PR+SD | 70.8 (58.9 to 81.0) |
| CR | 6.9 (2.3 to 15.5) |
| PR | 5.6 (1.5 to 13.6) |
Hematologic improvements (HI) have 4 categories: 1. Erythroid response (HI-E): Major \>20g/L increase or transfusion independent. Minor: 10-20g/L increase or ≥50% decrease in transfusion requirements. 2. Platelet response (HI-P): Major absolute increase of ≥30x10\^9/L or platelet transfusion independence. Minor: ≥50% increase. 3. Neutrophil response (HI-N): Major 100% increase or an absolute increase of \>0.5x10\^9/L. Minor: ≥100% increase and absolute increase of \<0.5x10\^9/L 4. Progression or relapse after HI Hematological improvement (HI) was defined as any type (major or minor) of improvement of HI-E, HI-P, or HI-N. Criteria: Pretreatment=hemoglobin \<100g/L or RBC transfusion-dependent, platelet count \<100x10\^9/L or platelet transfusion dependent, absolute neutrophil count \<1.5x10\^9/L. Sponsor's determination was derived using clinically relevant data. Denominator for progression/relapse after HI included participants who had achieved HI.
| percentage of participants | Azacitidine |
|---|---|
| Any improvement | 52.8 (40.7 to 64.7) |
| Hematologic Improvement-E (major) | 35.8 (24.5 to 48.5) |
| Hematologic Improvement-E (minor) | 9.0 (3.4 to 18.5) |
| Hematologic Improvement-P (major) | 37.9 (25.5 to 51.6) |
| Hematologic Improvement-P (minor) | 0.0 (0.0 to 6.2) |
| Hematologic Improvement-N (major) | 21.8 (11.8 to 35.0) |
| Hematologic Improvement-N (minor) | 0.0 (0.0 to 6.5) |
The number of units of platelet transfusions received 56 days prior to treatment, considered the baseline period, (baseline period defined as the screening period before the date of the first dose of azacitidine; any laboratory and blood transfusion data reported on the day of the first dose of azacitidine was considered to be baseline data) and during study was standardized per 28 days and summarized by cycle for platelets. The formula for standardizing per 28 days was: \[(# of transfusions in the measurement period / length of the measurement period (days)) x 28\], where the measurement period was either baseline or the relevant cycle length.
| Units of platelet transfusions | Azacitidine |
|---|---|
| Baseline N = 72 | 1.9 ± 4.91 |
| Overall Post-Baseline Average N = 72 | 4.7 ± 17.79 |
| Overall Change from Baseline N = 72 | 2.8 ± 17.89 |
| Cycle 1 N = 72 | 5.2 ± 18.83 |
| Cycle 2 | 2.4 ± 5.86 |
| Cycle 3 | 3.3 ± 11.44 |
| Cycle 4 | 2.7 ± 6.13 |
| Cycle 5 | 2.5 ± 7.69 |
| Cycle 6 | 1.5 ± 4.15 |
| Cycle 7 | 1.0 ± 2.84 |
| Cycle 8 | 1.1 ± 2.05 |
| Cycle 9 | 0.8 ± 2.46 |
| Cycle 10 | 0.8 ± 2.08 |
| Cycle 11 | 0.5 ± 1.00 |
| Cycle 12 | 0.3 ± 0.78 |
| Cycle 13 | 0.3 ± 0.72 |
| Cycle 14 | 0.1 ± 0.35 |
| Cycle 15 | 0.3 ± 0.90 |
| Cycle 16 | 0.3 ± 0.90 |
| Cycle 17 | 0.3 ± 0.73 |
| Cycle 18 | 0.6 ± 1.51 |
| Cycle 19 | 0.3 ± 0.64 |
| Cycle 20 | 0.2 ± 0.37 |
| Cycle 21 | 0.0 ± 0.00 |
| Cycle 22 | 0.0 ± NA |
| Cycle 23 | 0.0 ± NA |
| Cycle 24 | 0.0 ± NA |
| Cycle 25 | 0.0 ± NA |
| Cycle 26 | 0.0 ± NA |
| Cycle 27 | 0.0 ± NA |
The number of platelet transfusions received 56 days prior to treatment, considered the baseline period (baseline period defined as the screening period before the date of the first dose of azacitidine; any laboratory and blood transfusion data reported on the day of the first dose of azacitidine was considered to be baseline data) and during study was standardized per 28 days and summarized by cycle for platelets. The formula for standardizing per 28 days was: \[(# of transfusions in the measurement period / length of the measurement period (days)) x 28\], where the measurement period was either baseline or the relevant cycle length.
| Platelet transfusions | Azacitidine |
|---|---|
| Baseline N = 72 | 0.8 ± 2.36 |
| Overall Post-Baseline Average N = 72 | 1.6 ± 2.83 |
| Overall Change from Baseline N = 72 | 0.8 ± 3.29 |
| Cycle 1 N = 72 | 1.8 ± 2.89 |
| Cycle 2 | 1.3 ± 2.59 |
| Cycle 3 | 1.2 ± 2.28 |
| Cycle 4 | 1.3 ± 2.18 |
| Cycle 5 | 0.9 ± 1.58 |
| Cycle 6 | 0.7 ± 1.34 |
| Cycle 7 | 0.8 ± 2.50 |
| Cycle 8 | 0.8 ± 1.66 |
| Cycle 9 | 0.8 ± 2.46 |
| Cycle 10 | 0.8 ± 2.08 |
| Cycle 11 | 0.5 ± 1.00 |
| Cycle 12 | 0.3 ± 0.78 |
| Cycle 13 | 0.3 ± 0.72 |
| Cycle 14 | 0.1 ± 0.35 |
| Cycle 15 | 0.3 ± 0.90 |
| Cycle 16 | 0.3 ± 0.90 |
| Cycle 17 | 0.3 ± 0.73 |
| Cycle 18 | 0.6 ± 1.51 |
| Cycle 19 | 0.3 ± 0.64 |
| Cycle 20 | 0.2 ± 0.37 |
| Cycle 21 | 0.0 ± 0.00 |
| Cycle 22 | 0.0 ± NA |
| Cycle 23 | 0.0 ± NA |
| Cycle 24 | 0.0 ± NA |
| Cycle 25 | 0.0 ± NA |
| Cycle 26 | 0.0 ± NA |
| Cycle 27 | 0.0 ± NA |
The number of units of RBC received 56 days prior to treatment, considered the baseline period (baseline period defined as the screening period before the date of the first dose of azacitidine; any laboratory and blood transfusion data reported on the day of the first dose of azacitidine was considered to be baseline data) and during study was standardized per 28 days and summarized by cycle for RBC. The formula for standardizing per 28 days was: \[(# of transfusions in the measurement period / length of the measurement period (days)) x 28\], where the measurement period was either baseline or the relevant cycle length.
| Units of RBC Transfusions | Azacitidine |
|---|---|
| Baseline N = 72 | 2.3 ± 3.55 |
| Overall Post-Baseline Average N = 72 | 3.5 ± 3.88 |
| Overall Change from Baseline N = 72 | 1.2 ± 4.34 |
| Cycle 1 N = 72 | 3.6 ± 3.41 |
| Cycle 2 | 3.6 ± 4.88 |
| Cycle 3 | 3.0 ± 3.68 |
| Cycle 4 | 2.7 ± 3.73 |
| Cycle 5 | 2.5 ± 3.94 |
| Cycle 6 | 2.0 ± 3.46 |
| Cycle 7 | 1.7 ± 3.84 |
| Cycle 8 | 1.7 ± 2.68 |
| Cycle 9 | 0.9 ± 1.56 |
| Cycle 10 | 1.2 ± 2.25 |
| Cycle 11 | 1.3 ± 1.97 |
| Cycle 12 | 1.1 ± 2.21 |
| Cycle 13 | 1.2 ± 2.62 |
| Cycle 14 | 0.4 ± 1.05 |
| Cycle 15 | 1.1 ± 2.07 |
| Cycle 16 | 0.9 ± 1.61 |
| Cycle 17 | 1.2 ± 3.28 |
| Cycle 18 | 1.6 ± 3.07 |
| Cycle 19 | 0.8 ± 1.37 |
| Cycle 20 | 1.1 ± 1.42 |
| Cycle 21 | 0.4 ± 0.62 |
| Cycle 22 N | 0 ± NA |
| Cycle 23 | 0.0 ± NA |
| Cycle 24 | 0.0 ± NA |
| Cycle 25 | 0.0 ± NA |
| Cycle 26 | 0.0 ± NA |
| Cycle 27 | 0.0 ± NA |
The number of RBC transfusions received 56 days prior to treatment, considered the baseline period (baseline period defined as the screening period before the date of the first dose of azacitidine; any laboratory and blood transfusion data reported on the day of the first dose of azacitidine was considered to be baseline data) and during study was standardized per 28 days and summarized by cycle for platelets. The formula for standardizing per 28 days was: \[(# of transfusions in the measurement period / length of the measurement period (days)) x 28\], where the measurement period was either baseline or the relevant cycle length.
| RBC Transfusions | Azacitidine |
|---|---|
| Baseline N = 72 | 1.1 ± 1.79 |
| Overall Post-Baseline Average N = 72 | 1.6 ± 1.97 |
| Overall Change from Baseline N = 72 | 0.5 ± 2.12 |
| Cycle 1 N = 72 | 1.7 ± 1.64 |
| Cycle 2 | 1.7 ± 2.56 |
| Cycle 3 | 1.4 ± 1.81 |
| Cycle 4 | 1.2 ± 1.73 |
| Cycle 5 | 1.1 ± 1.81 |
| Cycle 6 | 0.9 ± 1.63 |
| Cycle 7 | 0.8 ± 1.97 |
| Cycle 8 | 0.8 ± 1.23 |
| Cycle 9 | 0.4 ± 0.74 |
| Cycle 10 | 0.5 ± 0.94 |
| Cycle 11 | 0.5 ± 0.78 |
| Cycle 12 | 0.4 ± 0.87 |
| Cycle 13 | 0.5 ± 0.94 |
| Cycle 14 | 0.2 ± 0.53 |
| Cycle 15 | 0.4 ± 0.77 |
| Cycle 16 | 0.4 ± 0.57 |
| Cycle 17 | 0.3 ± 0.91 |
| Cycle 18 | 0.7 ± 1.17 |
| Cycle 19 | 0.4 ± 0.64 |
| Cycle 20 | 0.6 ± 0.71 |
| Cycle 21 | 0.2 ± 0.31 |
| Cycle 22 | 0.0 ± NA |
| Cycle 23 | 0.0 ± NA |
| Cycle 24 | 0.0 ± NA |
| Cycle 25 | 0.0 ± NA |
| Cycle 26 | 0.0 ± NA |
| Cycle 27 | 0.0 ± NA |
The on-treatment adverse event of infection requiring IV antibiotics, antifungals, or antivirals per 28 days/cycle. The overall post-baseline average is the average of number of infections requiring IV antibiotics or IV antiviral per 28 days/cycle.
| Infections | Azacitidine |
|---|---|
| Baseline N = 72 | 0.0 ± 0.20 |
| Overall Post Baseline Average N = 72 | 0.6 ± 1.43 |
| Overall Change from Baseline N =72 | 0.5 ± 1.45 |
| Cycle 1 N = 72 | 0.6 ± 1.32 |
| Cycle 2 | 0.5 ± 1.67 |
| Cycle 3 | 0.4 ± 0.86 |
| Cycle 4 | 0.5 ± 1.03 |
| Cycle 5 | 0.4 ± 0.72 |
| Cycle 6 | 0.2 ± 0.61 |
| Cycle 7 | 0.3 ± 1.01 |
| Cycle 8 | 0.2 ± 0.47 |
| Cycle 9 | 0.1 ± 0.32 |
| Cycle 10 | 0.2 ± 0.44 |
| Cycle 11 | 0.1 ± 0.31 |
| Cycle12 | 0.1 ± 0.27 |
| Cycle 13 | 0.1 ± 0.24 |
| Cycle 14 15 | 0.1 ± 0.32 |
| Cycle 15 | 0.3 ± 0.70 |
| Cycle 16 | 0.3 ± 0.42 |
| Cycle 17 | 0.4 ± 0.75 |
| Cycle 18 | 0.4 ± 0.74 |
| Cycle 19 | 0.2 ± 0.41 |
| Cycle 20 | 0.0 ± 0.00 |
| Cycle 21 | 0.0 ± 0.00 |
| Cycle 22 | 0.9 ± NA |
| Cycle 23 | 1.0 ± NA |
| Cycle 24 | 0.0 ± NA |
| Cycle 25 | 0.0 ± NA |
| Cycle 26 N | 0.0 ± NA |
| Cycle 27 | 0.0 ± NA |
Overall survival is defined as time to death from any cause, is calculated using date of first dose and date of death, or date of last follow-up for censored participants. Those, who die regardless of the cause of death, will be considered to have an event.
| months | Azacitidine |
|---|---|
| Median OS | 22.0 (15.1 to NA) |
| 25th percentile OS | 8.5 (6.1 to 13.8) |
| 75th Percentile OS | NA (24.2 to NA) |
A treatment-emergent adverse events (TEAE) was defined as AEs with an onset date on or after the date of first dose and within 28 days after the date of the last dose. Any AE that occurred beyond this timeframe and was assessed by the investigator as possibly related to study drug was considered treatment-emergent. The intensity and severity of AEs was assessed by the investigator according to the Common Terminology Criteria for Adverse Event (CTCAE) Version 4.0. For any AEs not listed in the CTCAE grading system, the intensities of these events was assessed by the Investigator using the 5-point scale: Grade 1 = Mild, Grade 2 = Moderate; Grade 3 = Severe, Grade 4 = Life threatening, Grade 5 = Death. An SAE is any AE occurring that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and constitutes an important medical event.
| participants | Azacitidine |
|---|---|
| ≥ 1 TEAE | 72 |
| ≥ 1 Grade 3 or 4 TEAE | 70 |
| ≥ 1 TEAE related to study drug | 68 |
| ≥ 1 Grade 3 or 4 TEAE related to study drug | 59 |
| ≥ 1 serious TEAE | 38 |
| ≥ 1 Grade 3 or 4 serious TEAE | 33 |
| ≥ 1 serious TEAE related to study drug | 28 |
| ≥ 1 TEAE leading to discontinuation of study drug | 14 |
| ≥ 1 TEAE leading to dose reduction of study drug | 19 |
| ≥1 TEAE leading to dose interruption of study drug | 49 |
| ≥1 TEAE leading to dose reduction/interruption | 50 |
| ≥1 TEAE with outcome of death | 11 |
Area under the plasma concentration-time curve from time zero to infinity (AUC∞) following multiple doses of Azacitidine on Day 7; if possible, the area under the concentration-time curve from time zero to infinity, calculated by the linear trapezoidal rule and extrapolated to infinity was calculated according to the following equation: AUC∞ = AUCt + (Ct/ λz ), where Ct is the last quantifiable concentration. No AUC extrapolation will be performed with unreliable λz. If % AUC extrapolated is ≥ 25%, AUC∞ will not be reported
| ng*h/mL | Azacitidine |
|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of Azacitidine | 1172.6 ± 18.0 |
Area under the plasma concentration-time curve from time zero to the last quantifiable time point, calculated by the linear trapezoidal rule when concentrations are increasing and the logarithmic trapezoidal method when concentrations are decreasing.
| ng*h/mL | Azacitidine |
|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUCt) of Azacitidine | 1161.9 ± 17.7 |
The observed maximum plasma concentration obtained directly from the observed concentration versus time data.
| ng/mL | Azacitidine |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Azacitidine | 1264.6 ± 30.7 |
Time to maximum observed plasma concentration obtained directly from the observed concentration versus time data.
| hours | Azacitidine |
|---|---|
| Time to Maximum Plasma Concentration (Tmax) of Azacitidine | 0.25 ± 27.66 |
The apparent terminal half-life was calculated according to the following equation t½ = 0.693/λz.
| hours | Azacitidine |
|---|---|
| Terminal Phase of Half-life (T1/2) of Azacitidine | 0.8 ± 69.0 |
Apparent total plasma clearance (CL/F) of Azacitidine was calculated as Dose/AUC∞
| Liters/hours | Azacitidine |
|---|---|
| Apparent Total Plasma Clearance (CL/F) of Azacitidine | 107.2 ± 19.1 |
Apparent volume of distribution, was calculated according to the equation: Vd/F = (CL/F)/λz
| Liters | Azacitidine |
|---|---|
| Apparent Volume of Distribution (Vd/F) of Azacitidine | 121.5 ± 65.1 |
A treatment-emergent adverse events (TEAE) was defined as AEs with an onset date on or after the date of first dose and within 28 days after the date of the last dose. Any AE that occurred beyond this timeframe and was assessed by the investigator as possibly related to study drug was considered treatment-emergent. The intensity and severity of AEs was assessed by the investigator according to the Common Terminology Criteria for Adverse Event (CTCAE) Version 4.0. For any AEs not listed in the CTCAE grading system, the intensities of these events was assessed by the Investigator using the 5-point scale: Grade 1 = Mild, Grade 2 = Moderate; Grade 3 = Severe, Grade 4 = Life threatening, Grade 5 = Death. An SAE is any AE occurring that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and constitutes an important medical event.
| participants | Azacitidine |
|---|---|
| ≥ 1 TEAE | 14 |
| ≥ 1 TEAE related to study drug | 8 |
| ≥ 1 Grade 3 or 4 TEAE | 13 |
| ≥ 1 Grade 3 or 4 TEAE related to study drug | 6 |
| ≥ 1 serious TEAE | 5 |
| ≥ 1 serious TEAE related to study drug | 1 |
| ≥ 1 Grade 3 or 4 serious TEAE | 5 |
| ≥1 TEAE leading to dose interruption of study drug | 4 |
| ≥1 TEAE leading to dose reduction/interruption | 4 |
Collected over Azacitidine Exposure across all cycles: median duration of azacitidine treatment was 786 days (range 428 to 1507).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Azacitidine - Parent Phase | 13/72 (18.1%) | 38/72 (52.8%) | 72/72 (100%) |
| Azacitdine - Extension Phase | 0/15 (0%) | 5/15 (33.3%) | 14/15 (93.3%) |
| Event | Azacitidine - Parent Phase | Azacitdine - Extension Phase |
|---|---|---|
| PneumoniaInfections and infestations | 11/72 | 1/15 |
| AnaemiaBlood and lymphatic system disorders | 1/72 | 2/15 |
| Lung infectionInfections and infestations | 2/72 | 2/15 |
| Febrile neutropeniaBlood and lymphatic system disorders | 5/72 | 0/15 |
| Cardiac failureCardiac disorders | 2/72 | 1/15 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/72 | 1/15 |
| ErythropeniaBlood and lymphatic system disorders | 0/72 | 1/15 |
| EnteritisGastrointestinal disorders | 0/72 | 1/15 |
| Rhinitis AllergicRespiratory, thoracic and mediastinal disorders | 0/72 | 1/15 |
| Renal Failure, AcuteRenal and urinary disorders | 0/72 | 1/15 |
| Event | Azacitidine - Parent Phase | Azacitdine - Extension Phase |
|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 52/72 | 10/15 |
| LeukopeniaBlood and lymphatic system disorders | 48/72 | 10/15 |
| NeutropeniaBlood and lymphatic system disorders | 48/72 | 6/15 |
| AnaemiaBlood and lymphatic system disorders | 38/72 | 6/15 |
| Upper respiratory tract infectionInfections and infestations | 27/72 | 1/15 |
| ConstipationGastrointestinal disorders | 22/72 | 1/15 |
| PyrexiaGeneral disorders | 21/72 | 2/15 |
| NauseaGastrointestinal disorders | 19/72 | 3/15 |
| PneumoniaInfections and infestations | 19/72 | 1/15 |
| GingivitisInfections and infestations | 16/72 | 2/15 |
ITT includes all participants who had been screened and enrolled into the study.
| Age, Continuous(years) | Azacitidine |
|---|---|
| Mean | 54.3 ± 11.78 |
| Sex: Female, Male(Participants) | Azacitidine |
|---|---|
| Female | 34 |
| Male | 38 |
| International Prognostic Scoring System (IPSS) Risk Classification(Participants) | Azacitidine |
|---|---|
| Low (0) | 0 |
| Intermediate 1 (0.5-1.0) | 0 |
| Intermediate 2 (1.5-2.0) | 47 |
| High (>=2.5) | 25 |
| French-American-British classification (FAB)(Participants) | Azacitidine |
|---|---|
| RAEB=Refractory anemia with excess blasts | 63 |
| RAEB in transformation | 8 |
| Modified CMML=Chronic myelomonocytic leukemia | 1 |
| MDS World Health Organization (WHO) Classification(Participants) | Azacitidine |
|---|---|
| RAEB-1=Refractory anemia with excess blasts | 14 |
| RAEB -2 with MPD=Myeloproliferative disease | 50 |
| Acute Myelogenous Leukemia (AML) | 7 |
| CMML | 1 |
| MDS and myeloproliferative disease (MPD) | 0 |
Ran from Jul 2012 to primary completion in Jan 2015, 30 months.
Results were first posted in Feb 2016, 1 year 1 month after primary completion.
Of 52 industry-sponsored phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 30 months is below that.
Counting every sponsor, half of 279 studies reached it within 66 months; a quarter within 40 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Azacitidine